|
Dr. Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 30 years experience. In 2003, he co-founded NOVACE Corporation, a network of entrepreneurs providing scientific, and strategic management solutions to the biotechnology industry and venture capital community; in 2000 he joined Psychiatric Genomics, where he was Founder, CSO and President of a biotechnology company developing genome-based approaches to drug discovery for the treatment of Mental Illness. From 1994-2000 he was Senior Vice President of Research & Development at Scriptgen (Anadys) Pharmaceuticals, that developed a genomic-based drug discovery platform in infectious diseases. From 1975 to 1994, Michael held a number of senior positions at Marion Merrell Dow Research Institute (Aventis), including Vice President Research, North America. From 1970 to 1975 Michael was Head of Biochemical Pharmacology at Beecham Pharmaceuticals (GlaxoSmithKline) where he pioneered rational biochemical approaches to drug discovery with three compounds demonstrating clinical effectiveness. Michael received both his Ph.D. and D.Sc. from the University of Nottingham in neuroscience and rational drug design of CNS active drugs, respectively. He has been an invited speaker and chairperson for a number of international and national conferences, is co-inventor on 35 issued US patents, 3 pending patents and co-author of over 150 scientific articles and book chapters. | 